Elderly Onset of Functional Motor Disorders: Clinical Correlates from the Italian Registry.

elderly onset functional motor disorders functional neurological disorders functional parkinsonism neurological comorbidities

Journal

Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279

Informations de publication

Date de publication:
Jan 2024
Historique:
revised: 06 10 2023
received: 11 07 2023
accepted: 13 10 2023
medline: 31 1 2024
pubmed: 31 1 2024
entrez: 31 1 2024
Statut: ppublish

Résumé

Functional motor disorders (FMD) are a frequent neurological condition affecting patients with movement disorders. Commonly described in younger adults, their manifestation can be also associated to an elderly onset. To assess the prevalence and describe the clinical manifestations of FMD with elderly and younger onset and their relationship with demographical and clinical variables. We recruited patients with a "clinically definite" diagnosis of FMD from the Italian Registry of FMD. Patients underwent extensive clinical assessments. For elderly onset, we set a chronological cut-off at 65 years or older according to WHO definition. Multivariate regression models were implemented to estimate adjusted odds ratio of elderly FMD onset related to clinical characteristics. Among the 410 patients, 34 (8.2%) experienced elderly-onset FMD, with a mean age at onset of 70.9 years. The most common phenotype was tremor (47.1%), followed by gait disorders, weakness, and dystonia (29.4%, 23.5%, 14.7%, respectively). Eleven elderly patients had a combined phenomenology: 9 exhibited two phenotypes, 2 had three phenotypes. Weakness was isolated in 3/8 patients and combined with another phenotype in 5/8, manifesting as paraplegia (n = 4); upper limb diplegia (n = 2), hemiparesis/hemiplegia (n = 1), and tetraparesis/tetraplegia (n= 1). Non-motor and other functional neurological disorders occurred more frequently in the younger group (89.1%) than the elderly (73.5%). Neurological and non-neurological comorbidities were more prevalent in the elderly group (82.4%) as opposed to the younger (32.7%). In a multivariate regression analysis, elderly-onset FMD was significantly associated with neurological comorbidities, including parkinsonism (OR 6.73) and cerebrovascular diseases (OR 5.48). These results highlight the importance of achieving an accurate diagnosis of FMD in the elderly, as it is crucial for effectively managing FMD symptoms and addressing neurological comorbidities.

Sections du résumé

BACKGROUND BACKGROUND
Functional motor disorders (FMD) are a frequent neurological condition affecting patients with movement disorders. Commonly described in younger adults, their manifestation can be also associated to an elderly onset.
OBJECTIVE OBJECTIVE
To assess the prevalence and describe the clinical manifestations of FMD with elderly and younger onset and their relationship with demographical and clinical variables.
METHODS METHODS
We recruited patients with a "clinically definite" diagnosis of FMD from the Italian Registry of FMD. Patients underwent extensive clinical assessments. For elderly onset, we set a chronological cut-off at 65 years or older according to WHO definition. Multivariate regression models were implemented to estimate adjusted odds ratio of elderly FMD onset related to clinical characteristics.
RESULTS RESULTS
Among the 410 patients, 34 (8.2%) experienced elderly-onset FMD, with a mean age at onset of 70.9 years. The most common phenotype was tremor (47.1%), followed by gait disorders, weakness, and dystonia (29.4%, 23.5%, 14.7%, respectively). Eleven elderly patients had a combined phenomenology: 9 exhibited two phenotypes, 2 had three phenotypes. Weakness was isolated in 3/8 patients and combined with another phenotype in 5/8, manifesting as paraplegia (n = 4); upper limb diplegia (n = 2), hemiparesis/hemiplegia (n = 1), and tetraparesis/tetraplegia (n= 1). Non-motor and other functional neurological disorders occurred more frequently in the younger group (89.1%) than the elderly (73.5%). Neurological and non-neurological comorbidities were more prevalent in the elderly group (82.4%) as opposed to the younger (32.7%). In a multivariate regression analysis, elderly-onset FMD was significantly associated with neurological comorbidities, including parkinsonism (OR 6.73) and cerebrovascular diseases (OR 5.48).
CONCLUSIONS CONCLUSIONS
These results highlight the importance of achieving an accurate diagnosis of FMD in the elderly, as it is crucial for effectively managing FMD symptoms and addressing neurological comorbidities.

Identifiants

pubmed: 38291844
doi: 10.1002/mdc3.13916
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

38-44

Informations de copyright

© 2023 The Authors. Movement Disorders Clinical Practice published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Références

Espay AJ, Aybek S, Carson A, et al. Current concepts in diagnosis and treatment of functional neurological disorders. JAMA Neurol 2018;75(9):1132-1141.
Edwards MJ, Bhatia KP. Functional (psychogenic) movement disorders: merging mind and brain. Lancet Neurol 2012;11(3):250-260.
Tinazzi M, Geroin C, Erro R, et al. Functional motor disorders associated with other neurological diseases: beyond the boundaries of "organic" neurology. Eur J Neurol 2021;28(5):1752-1758.
Tinazzi M, Morgante F, Marcuzzo E, et al. Clinical Correlates of Functional Motor Disorders: An Italian Multicentre Study. Movement Disorders Clinical Practice;n/a(n/a).
Factor SA, Podskalny GD, Molho ES. Psychogenic movement-disorders - frequency, clinical profile, and characteristics. J Neurol Neurosur Ps 1995;59(4):406-412.
Lidstone SC, Costa-Parke M, Robinson EJ, Ercoli T, Stone J, Group FGS. Functional movement disorder gender, age and phenotype study: a systematic review and individual patient meta-analysis of 4905 cases. J Neurol Neurosurg Psychiatry 2022;93(6):609-616.
Matzold S, Geritz J, Zeuner KE, et al. Functional movement disorders in neurogeriatric inpatients: underdiagnosed, often comorbid to neurodegenerative disorders and treatable. Z Gerontol Geriatr 2019;52(4):324-329.
Batla A, Stamelou M, Edwards MJ, Pareés I, Saifee TA, Fox Z, Bhatia KP. Functional movement disorders are not uncommon in the elderly. Mov Disord 2013;28(4):540-543.
Chouksey A, Pandey S. Functional movement disorders in elderly. Tremor Other Hyperkinet Mov (N Y) 2019;9:9.
World Health Organisation. Definition of an Older or Elderly Person. Geneva, Switzerland. http://wwwwhoint/healthinfo/survey/ageingdefnolder/en/indexhtml: WHO; 2010.
Stone J, Carson A, Duncan R, et al. Which neurological diseases are most likely to be associated with "symptoms unexplained by organic disease". J Neurol 2012;259(1):33-38.
Moscovich M, LaFaver K, Maetzler W. Functional movement disorder in older adults. In: LaFaver K, Maurer CW, Nicholson TR, Perez DL, eds. Functional Movement Disorder: an Interdisciplinary Case-Based Approach. Cham: Springer International Publishing; 2022:197-203.
Gupta A, Lang AE. Psychogenic movement disorders. Curr Opin Neurol 2009;22(4):430-436.
Lal BK, Cires-Drouet RS. Cerebrovascular disease in the elderly. In: Chaer R, ed. Vascular Disease in Older Adults: A Comprehensive Clinical Guide. Cham: Springer International Publishing; 2017:113-125.
LaFaver K, Lang AE, Stone J, et al. Opinions and clinical practices related to diagnosing and managing functional (psychogenic) movement disorders: changes in the last decade. Eur J Neurol 2020;27(6):975-984.
Stone J, Warlow C, Sharpe M. The symptom of functional weakness: a controlled study of 107 patients. Brain 2010;133:1537-1551.
Gelauff JM, Kingma EM, Kalkman JS, et al. Fatigue, not self-rated motor symptom severity, affects quality of life in functional motor disorders. J Neurol 2018;265(8):1803-1809.
Butler M, Shipston-Sharman O, Seynaeve M, et al. International online survey of 1048 individuals with functional neurological disorder. Eur J Neurol 2021;28(11):3591-3602.

Auteurs

Christian Geroin (C)

Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Martina Petracca (M)

Movement Disorder Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Sonia Di Tella (S)

Department of Psychology, Università Cattolica del Sacro Cuore, Milan, Italy.

Enrico Marcuzzo (E)

Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Roberto Erro (R)

Center for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Dentistry-Scuola Medica Salernitana, University of Salerno, Baronissi, Italy.

Sofia Cuoco (S)

Center for Neurodegenerative Diseases (CEMAND), Department of Medicine, Surgery and Dentistry-Scuola Medica Salernitana, University of Salerno, Baronissi, Italy.

Roberto Ceravolo (R)

Center for NeuroDegenerative Diseases Parkinson and Movement Disorders, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Sonia Mazzucchi (S)

Center for NeuroDegenerative Diseases Parkinson and Movement Disorders, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Andrea Pilotto (A)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
FERB Onlus, Ospedale S. Isidoro, Trescore Balneario, Bergamo, Italy.

Alessandro Padovani (A)

Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Luigi Michele Romito (LM)

Parkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Roberto Eleopra (R)

Parkinson and Movement Disorders Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Mario Zappia (M)

Department G.F. Ingrassia, Section of Neurosciences, University of Catania, Catania, Italy.

Alessandra Nicoletti (A)

Department G.F. Ingrassia, Section of Neurosciences, University of Catania, Catania, Italy.

Carlo Dallocchio (C)

Department of Medical Area, Neurology Unit, ASST Pavia, Pavia, Italy.

Carla Arbasino (C)

Department of Medical Area, Neurology Unit, ASST Pavia, Pavia, Italy.

Francesco Bono (F)

Botulinum Toxin Center, Neurology Unit A.O.U. Mater Domini, Catanzaro, Italy.

Vincenzo Laterza (V)

Botulinum Toxin Center, Neurology Unit A.O.U. Mater Domini, Catanzaro, Italy.

Benedetta Demartini (B)

Aldo Ravelli Research Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Milan, Italy.

Orsola Gambini (O)

Aldo Ravelli Research Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Milan, Italy.

Nicola Modugno (N)

IRCCS Neuromed, Pozzilli, Italy.

Enrica Olivola (E)

IRCCS Neuromed, Pozzilli, Italy.

Laura Bonanni (L)

Department of Medicine and Aging Sciences, University G. d'Annunzio, Chieti-Pescara, Italy.

Alberto Albanese (A)

Department of Neurology, IRCCS Humanitas Research Hospital, Rozzano, Italy.

Gina Ferrazzano (G)

Department of Human Neurosciences, Università La Sapienza, Rome, Italy.

Alessandro Tessitore (A)

Department of Advanced Medical and Surgery Sciences, University of Campania-Luigi Vanvitelli, Naples, Italy.

Leonardo Lopiano (L)

Department of Neuroscience-Rita Levi Montalcini, University of Turin, Turin, Italy.

Giovanna Calandra-Buonaura (G)

Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.

Francesca Morgante (F)

Neurosciences Research Centre, Molecular and Clinical Sciences Neurosciences Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, United Kingdom.
Department of Experimental and Clinical Medicine, University of Messina, Messina, Italy.

Marcello Esposito (M)

Clinical Neurophysiology Unit, Cardarelli Hospital, Naples, Italy.

Antonio Pisani (A)

Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
IRCCS Mondino Foundation, Pavia, Italy.

Paolo Manganotti (P)

Clinical Neurology Unit, Department of Medical, Surgical and Health Services, University of Trieste, Trieste, Italy.

Lucia Tesolin (L)

Functional Movement Disorders Outpt.Clinic, Clinical Neurology and Stroke Unit Dep., Central Country Hospital, Bolzano, Italy.

Francesco Teatini (F)

Functional Movement Disorders Outpt.Clinic, Clinical Neurology and Stroke Unit Dep., Central Country Hospital, Bolzano, Italy.

Serena Camozzi (S)

Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Tommaso Ercoli (T)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Fabrizio Stocchi (F)

University and Institute of Research and Medical Care San Raffaele Roma, Rome, Italy.

Mario Coletti Moja (M)

Ospedale degli Infermi, Department of Neurology, Ponderano, Italy.

Giovanni Defazio (G)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Michele Tinazzi (M)

Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.

Classifications MeSH